Case-Based Peer Perspectives: A 65-Year-Old Woman with Metastatic Breast Cancer

Expert oncologist Kevin Kalinsky, MD, reviews the diagnosis and management of a 65-year old woman with HR+/HER2-low metastatic breast cancer.

Comprehensive insight to the treatment armamentarium for patients with HR+/HER2-low metastatic breast cancer and factors that help inform optimal sequencing.

Closing out his review of HR+/HER2-low metastatic breast cancer management, Kevin Kalinsky, MD, considers unmet needs and ongoing investigation into novel treatment strategies.

Expert perspectives on the mechanisms of resistance to frontline therapy in HR+/HER2- metastatic breast cancer and results from key clinical trials analyzing the safety and efficacy of rechallenging with prior therapy.

Key opinion leader Kevin Kalinsky, MD, MS, shares insight to recent and ongoing clinical trials with novel targeted therapies in the setting of HR+/HER2- metastatic breast cancer.

Closing out his discussion on HR+/HER2- metastatic breast cancer, Kevin Kalinsky, MD, MS, highlights key takeaways and shares excitement for future evolutions in the treatment paradigm.